Fundraising Fox
Belhaven Biopharma
Chapel Hill, US · Founded 2020 · Delaware corporation
Find your way into Belhaven Biopharma
Sign up to see every warm intro you have to Belhaven Biopharma
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Belhaven Biopharma team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Belhaven Bio develops a temperature-stable, needle-free delivery device for epinephrine and other emergency medications, designed to be more compact, affordable, and longer-lasting than traditional liquid injectables for patients with severe allergies and anaphylaxis conditions.
Founders & leadership
Belhaven Biopharma was founded in 2020 by Scott Lyman and Dave Neal.
SL
Scott LymanCEO and Co-Founder, Chairman of the BoardScott Lyman is CEO and co-founder of Belhaven Biopharma, which develops a temperature-stable, needle-free delivery device for epinephrine and emergency medications. His background includes expertise in business development, corporate finance, and R&D outsourcing.
DN
Dave NealCFO and Co-Founder, Board MemberDave Neal has over 30 years of experience in venture capital and early-stage financing, serving as a Venture Partner at Duke Capital Partners and as CFO at Belhaven Biopharma. He is also a Professor of the Practice of Entrepreneurship at UNC Kenan-Flagler Business School.
Board
WW
Wes WheelerBoard director
DW
Derek WinstanlyBoard director
Funding
SEC filings, press & company announcements$32.3M disclosed across 1 of 3 rounds · 2025
- Undisclosed amountSeed RoundJan 2025Source ↗
▶$32.3MraisedOct 2025 · 222 investors · PharmaceuticalsRule 506(b)
▶$32.3MraisedOct 2025 · 222 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Wes WheelerDirector
- David Algon NealExecutive Officer, Director
- Derek WinstanlyDirector
- Scott David LymanExecutive Officer, Director
- Offering amount
- $32.3M
- Amount sold
- $32.3M
- First sale
- Aug 2025
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
BiohavenBiohaven is a pharmaceutical company that discovers, develops, and commercializes medications for neurological and neuropsychiatric diseases, including epilepsy, pain, mood disorders, OCD, spinocerebellar ataxia, and spinal muscular atrophy. The company operates as a modern publicly traded entity and was acquired by Pfizer in May 2022 for approximately $13 billion.
Consumer ReportsConsumer Reports is an independent nonprofit that conducts rigorous product and service testing while surveying millions of consumers annually to report on marketplace issues and advocate for consumer rights, safety, digital protections, and financial fairness.
Companies working in the same space as Belhaven Biopharma.
In the news
Frequently asked questions
- What does Belhaven Biopharma do?
- Belhaven Bio develops a temperature-stable, needle-free delivery device for epinephrine and other emergency medications, designed to be more compact, affordable, and longer-lasting than traditional liquid injectables for patients with severe allergies and anaphylaxis conditions.
- Who founded Belhaven Biopharma?
- Belhaven Biopharma was founded by Scott Lyman, Dave Neal in 2020.
- How much funding has Belhaven Biopharma raised?
- Belhaven Biopharma has disclosed $32.3M raised across 1 of its 3 known rounds.
- Where is Belhaven Biopharma headquartered?
- Belhaven Biopharma is headquartered in Chapel Hill, US.